Inzen Therapeutics is a privately held, early-stage biotechnology company exploring ThanokineTM Biology as a surprising and important driver of disease. While the ability of living cells to respond to messages from other living cells is a well-established concept, Inzen has identified that living cells also respond to messages released by cells as they undergo turnover and die. We call these messages ThanokinesTM, and the way a cell undergoes turnover dramatically alters the ThanokinesTM that are released. ThanokinesTM can elicit a broad array of responses in living cells, and we have demonstrated that ThanokinesTM play a previously unrecognized role in the pathogenesis of a number of important diseases. Our mission is to pioneer a novel category of drugs based on manipulating Thanokine BiologyTM for the treatment of cancer, immune and fibrotic diseases, and regenerative processes.
Inzen Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences companies. Since 2000, Flagship has originated and fostered the development of nearly 100 scientific ventures resulting in $20+ billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.
Inzen Therapeutics offers the challenge and opportunity to work at an early stage, big concept biotechnology company. We are seeking a Principal Scientist to join as the founding member of our Translational Oncology/Immunology group, which will be focused on translating new targets and first-in-class drugs for Oncology and Immuno-oncology
The candidate will build and lead a translational research group primarily supporting cancer immunotherapy programs. The ideal candidate will have deep scientific experience in Oncology, with an emphasis on Immuno-Oncology. You will have a working knowledge of clinical development and past experience with developing PD models and mechanism of action studies, to support the translation of Inzen’s first programs into the clinic.
- Seed and build a Translational Oncology/Immunology team, supporting small molecules, biologics and gene therapy programs.
- Develop innovative preclinical animal models that enable interrogation of mechanisms of action, diagnostic hypotheses, and mechanisms of resistance, and define PK/PD/efficacy relationships. Oversee MoA studies both internally and at CROs.
- Provide scientific input and biomarker expertise for early oncology and immune-oncology programs. Work with leadership to develop and operationalize biomarker strategies for the programs.
- Manage translational efforts across teams in a highly matrixed organization, ensuring rapid execution and open communication
- Contribute to the writing of documents to support regulatory filings, patent applications and manuscripts published in peer-reviewed journals.
- PhD degree with 5-8 years’ industry experience, or BS or MS degree with 12 years relevant industry experience in Oncology/Immuno-oncology.
- Working knowledge of other functional areas of drug development, including toxicology and path to clinical development.
- Hands-on experience in the design, execution and generation of clinic-ready translational biomarker assays in oncology is a plus.
- Deep understanding of the role of translational research/medicine and clinical biomarkers in drug development.
- Demonstrated mechanistic understanding of disease biology in oncology and immuno-oncology in the context of drug development (small molecule preferred, familiarity with biologics a plus).
- Excellent communication skills across all levels within an organization and external.
- Demonstrated ability to lead and influence others in a highly matrixed work environment.
- Comfortable working in a fast-paced environment where speed is paramount.
Flagship Pioneering is committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.